Mitomycin Substipharm (Mitomycin)

Mitomycin is used as a local chemotherapeutic agent for urothelial malignancies.

• Superficial bladder carcinoma (stage Ta/T1): reduces tumor recurrence after transurethral resection.
• Carcinoma in situ of bladder: induces local tumor cell death to prevent progression.
• Recurrent non‑muscle‑invasive bladder cancer: prolongs disease‑free interval when administered intravesically.

• Mitomycin exerts its antineoplastic effect by forming covalent cross‑links between DNA strands. The drug alkylates the N2 position of guanine residues, preventing DNA unwinding and replication. This inhibition of DNA synthesis triggers apoptosis in rapidly dividing urothelial cells exposed to the intravesical solution. The cross‑linking is irreversible, leading to accumulation of DNA damage and activation of cell‑cycle checkpoints, which ultimately results in programmed cell death of malignant cells while sparing deeper tissues.

Mitomycin administered intravesically may be associated with a range of adverse reactions.

Common Side Effects

• Bladder irritation: burning sensation during or after instillation.
• Dysuria: painful urination following treatment.
• Urinary frequency: increased urge to void.
• Hematuria: presence of blood in urine.
• Chemical cystitis: inflammation of bladder lining.
• Mild nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects

• Severe bladder necrosis: extensive tissue damage requiring intervention.
• Systemic myelosuppression: reduced blood cell counts if drug is absorbed.
• Renal toxicity: impaired kidney function in susceptible patients.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Pulmonary fibrosis: rare scarring of lung tissue.
• Sepsis: systemic infection secondary to mucosal injury.

When using Mitomycin Substipharm, clinicians should observe specific safety measures.

• Renal function assessment: evaluate serum creatinine and glomerular filtration rate before each treatment.
• Urinary tract infection: ensure infection is treated and urine is sterile prior to instillation.
• Bladder capacity: confirm adequate bladder volume to tolerate the solution and avoid over‑distension.
• Concurrent systemic chemotherapy: avoid overlapping systemic exposure to reduce cumulative toxicity.
• Pregnancy and lactation: contraindicated unless benefits outweigh potential risks; discuss with patient.
• Store at room temperature: keep in original container, protect from light and moisture.

Mitomycin may interact with other medicines, influencing its safety or effectiveness.

Major Interactions (Avoid)

• Concomitant systemic chemotherapy agents (e.g., cyclophosphamide): increased risk of systemic toxicity.
• Nephrotoxic drugs (e.g., cisplatin): heightened potential for renal impairment.

Moderate Interactions (Monitor Closely)

• NSAIDs: may affect renal clearance and increase bladder irritation.
• Pelvic radiation therapy: can amplify local bladder toxicity.
• Anticoagulants: elevated risk of hematuria during treatment.